Is Pulse Biosciences Stock a Good Investment?
Pulse Biosciences Investment Advice | PLSE |
- Examine Pulse Biosciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Pulse Biosciences' leadership team and their track record. Good management can help Pulse Biosciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Pulse Biosciences' business and its evolving consumer preferences.
- Compare Pulse Biosciences' performance and market position to its competitors. Analyze how Pulse Biosciences is positioned in terms of product offerings, innovation, and market share.
- Check if Pulse Biosciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Pulse Biosciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Pulse Biosciences stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Pulse Biosciences is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Pulse Biosciences Stock
Researching Pulse Biosciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 72.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.82. Pulse Biosciences had not issued any dividends in recent years.
To determine if Pulse Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Pulse Biosciences' research are outlined below:
| Pulse Biosciences had very high historical volatility over the last 90 days | |
| Net Loss for the year was (42.21 M) with loss before overhead, payroll, taxes, and interest of (550 K). | |
| Pulse Biosciences currently holds about 14.8 M in cash with (33.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4. | |
| Pulse Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 72.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from thelincolnianonline.com: Pulse Biosciences Shares Gap Up Should You Buy |
Pulse Biosciences Quarterly Good Will |
|
Pulse Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Pulse Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Pulse Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Earnings surprises can significantly impact Pulse Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Pulse Biosciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.22 | -0.19 | 0.03 | 13 | ||
2023-05-11 | 2023-03-31 | -0.22 | -0.26 | -0.04 | 18 | ||
2022-08-10 | 2022-06-30 | -0.4 | -0.44 | -0.04 | 10 | ||
2019-04-30 | 2019-03-31 | -0.44 | -0.49 | -0.05 | 11 | ||
2024-05-07 | 2024-03-31 | -0.24 | -0.1837 | 0.0563 | 23 | ||
2022-05-11 | 2022-03-31 | -0.52 | -0.58 | -0.06 | 11 | ||
2020-11-09 | 2020-09-30 | -0.44 | -0.51 | -0.07 | 15 | ||
2021-02-22 | 2020-12-31 | -0.45 | -0.54 | -0.09 | 20 |
Pulse Biosciences Analyst Ratings
Pulse Biosciences' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Pulse Biosciences stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Pulse Biosciences' financials, market performance, and future outlook by experienced professionals. Pulse Biosciences' historical ratings below, therefore, can serve as a valuable tool for investors.Know Pulse Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulse Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulse Biosciences backward and forwards among themselves. Pulse Biosciences' institutional investor refers to the entity that pools money to purchase Pulse Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Westside Investment Management, Inc. | 2024-09-30 | 55 K | Bank Of New York Mellon Corp | 2024-09-30 | 40.3 K | Spotlight Asset Group, Inc. | 2024-06-30 | 40.3 K | Swiss National Bank | 2024-09-30 | 35.9 K | Goldman Sachs Group Inc | 2024-09-30 | 35.7 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 33.5 K | Barclays Plc | 2024-09-30 | 30.3 K | Tiaa Trust National Association | 2024-09-30 | 27.3 K | Rhumbline Advisers | 2024-09-30 | 25.8 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 995.8 K |
Pulse Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 992.88 M.Market Cap |
|
Pulse Biosciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.82) | (0.86) | |
| Return On Equity | (0.86) | (0.81) |
Determining Pulse Biosciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Pulse Biosciences is a good buy. For example, gross profit margin measures Pulse Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Pulse Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Pulse Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pulse Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pulse Biosciences' management manipulating its earnings.
Evaluate Pulse Biosciences' management efficiency
Pulse Biosciences has return on total asset (ROA) of (0.3815) % which means that it has lost $0.3815 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7028) %, meaning that it created substantial loss on money invested by shareholders. Pulse Biosciences' management efficiency ratios could be used to measure how well Pulse Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 2, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -1. At present, Pulse Biosciences' Debt To Assets are projected to increase slightly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 0.11, whereas Net Tangible Assets are forecasted to decline to about 26.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.06 | 1.01 | |
| Tangible Book Value Per Share | 0.95 | 1.49 | |
| Enterprise Value Over EBITDA | (11.74) | (12.33) | |
| Price Book Value Ratio | 15.24 | 16.01 | |
| Enterprise Value Multiple | (11.74) | (12.33) | |
| Price Fair Value | 15.24 | 16.01 | |
| Enterprise Value | 25.1 M | 26.4 M |
Leadership at Pulse Biosciences emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta 1.752 |
Basic technical analysis of Pulse Stock
As of the 2nd of January, Pulse Biosciences holds the Risk Adjusted Performance of 0.0317, coefficient of variation of 3460.04, and Semi Deviation of 4.39. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pulse Biosciences, as well as the relationship between them. Please check Pulse Biosciences treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Pulse Biosciences is priced some-what accurately, providing market reflects its current price of 17.8 per share. Given that Pulse Biosciences has jensen alpha of 0.1371, we recommend you to check out Pulse Biosciences's recent market performance to make sure the company can sustain itself at a future point.Pulse Biosciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulse Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulse Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulse Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pulse Biosciences' Outstanding Corporate Bonds
Pulse Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pulse Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pulse bonds can be classified according to their maturity, which is the date when Pulse Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| PulteGroup 6 percent Corp BondUS745867AT82 | View | |
| PulteGroup 55 percent Corp BondUS745867AW12 | View | |
| PulteGroup 5 percent Corp BondUS745867AX94 | View |
Understand Pulse Biosciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Pulse Biosciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0317 | |||
| Market Risk Adjusted Performance | 0.1204 | |||
| Mean Deviation | 3.82 | |||
| Semi Deviation | 4.39 | |||
| Downside Deviation | 4.46 | |||
| Coefficient Of Variation | 3460.04 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.27 | |||
| Information Ratio | 0.0268 | |||
| Jensen Alpha | 0.1371 | |||
| Total Risk Alpha | 0.1329 | |||
| Sortino Ratio | 0.0308 | |||
| Treynor Ratio | 0.1104 | |||
| Maximum Drawdown | 25.95 | |||
| Value At Risk | (5.64) | |||
| Potential Upside | 9.59 | |||
| Downside Variance | 19.9 | |||
| Semi Variance | 19.23 | |||
| Expected Short fall | (5.00) | |||
| Skewness | 0.0127 | |||
| Kurtosis | 1.23 |
| Risk Adjusted Performance | 0.0317 | |||
| Market Risk Adjusted Performance | 0.1204 | |||
| Mean Deviation | 3.82 | |||
| Semi Deviation | 4.39 | |||
| Downside Deviation | 4.46 | |||
| Coefficient Of Variation | 3460.04 | |||
| Standard Deviation | 5.13 | |||
| Variance | 26.27 | |||
| Information Ratio | 0.0268 | |||
| Jensen Alpha | 0.1371 | |||
| Total Risk Alpha | 0.1329 | |||
| Sortino Ratio | 0.0308 | |||
| Treynor Ratio | 0.1104 | |||
| Maximum Drawdown | 25.95 | |||
| Value At Risk | (5.64) | |||
| Potential Upside | 9.59 | |||
| Downside Variance | 19.9 | |||
| Semi Variance | 19.23 | |||
| Expected Short fall | (5.00) | |||
| Skewness | 0.0127 | |||
| Kurtosis | 1.23 |
Consider Pulse Biosciences' intraday indicators
Pulse Biosciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Pulse Biosciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Pulse Biosciences Corporate Filings
F4 | 20th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 19th of December 2024 Other Reports | ViewVerify | |
8K | 6th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 19th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Pulse Stock media impact
Far too much social signal, news, headlines, and media speculation about Pulse Biosciences that are available to investors today. That information is available publicly through Pulse media outlets and privately through word of mouth or via Pulse internal channels. However, regardless of the origin, that massive amount of Pulse data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulse Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulse Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulse Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulse Biosciences alpha.
Pulse Biosciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Pulse Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pulse Biosciences Corporate Management
| Patty Perla | Vice Resources | Profile | |
| Sandra Gardiner | CFO Admin | Profile | |
| JD Esq | General Secretary | Profile | |
| Gansevoort MD | Chief Officer | Profile | |
| Niv MD | Chief Surgery | Profile | |
| Richard Nuccitelli | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulse Biosciences. If investors know Pulse will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulse Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulse Biosciences is measured differently than its book value, which is the value of Pulse that is recorded on the company's balance sheet. Investors also form their own opinion of Pulse Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pulse Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulse Biosciences' market value can be influenced by many factors that don't directly affect Pulse Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Pulse Biosciences' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Pulse Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulse Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.